Physician profile
Andreas Kyprianou
NPI 1639126105
$38,906.44
in general payments reported to CMS, 2019-2025
37 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $6,420 · 2021: $2,060 · 2022: $4,397 · 2023: $418 · 2024: $396 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Education: $79.37 · Travel and Lodging: $50.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.81 |
| Education | $79.37 |
| Travel and Lodging | $50.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,415.88 | 2019-2025 | |
| Mylan Specialty L.P. | $14,005.38 | 2019-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $4,198.50 | 2019-2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $767.36 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $683.63 | 2019-2025 | Nucala |
| Insmed, INC. | $669.80 | 2019-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $376.52 | 2019-2021 | |
| United Therapeutics Corporation | $158.95 | 2019-2025 | Tyvaso |
| Stryker Corporation | $147.35 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $136.17 | 2023-2025 | Impella |
| Genentech USA, INC. | $128.22 | 2019 | |
| Ethicon INC. | $122.13 | 2022 | |
| Grifols USA, LLC | $120.44 | 2020-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $112.48 | 2019-2021 | |
| Philips North America LLC | $99.02 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $77.71 | 2020-2021 | |
| Verona Pharma, INC. | $69.91 | 2025 | Ohtuvayre |
| Circassia INC. | $59.78 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $57.95 | 2019-2020 | |
| Inspire Medical Systems, INC. | $54.29 | 2025 | Inspire |
| Electromed, INC. | $46.85 | 2019 | |
| Watermark Medical, INC. | $46.77 | 2020-2021 | |
| Shire North American Group INC | $39.13 | 2019 | |
| Mayne Pharma Commercial LLC | $35.16 | 2019 | |
| Gilead Sciences, INC. | $34.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.57 | 2019 | |
| Merck Sharp & Dohme LLC | $30.67 | 2019-2020 | |
| Ucb, INC. | $29.72 | 2019 | |
| Advanced Respiratory, INC | $26.35 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.08 | 2019 | |
| Harmony Biosciences LLC | $18.50 | 2020 | |
| Veran Medical Technologies, INC. | $15.32 | 2020 | |
| Vapotherm INC | $13.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.48 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.16 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Kyprianou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.